文献速递呼吸道感染呼吸危重症与机械通气

COVID-19中靶向GM-CSF:基于脆弱证据的方法

GM-CSF targeting in COVID-19: an approach based on fragile foundations.
PubMed 文献 · Eur Respir J · 2023-02-02

抗GM-CSF治疗COVID-19的试验结果不一致,可能源于基础生物学差异和研究结果的脆弱性。需要进一步研究COVID-19病理生理以更好靶向治疗。

要点

  • 抗GM-CSF治疗COVID-19试验结果存在分歧。
  • 结果差异可能与基础生物学和研究脆弱性有关。
  • 需进一步研究病理生理以优化靶向治疗。

核心结论

  • 抗GM-CSF治疗COVID-19的试验结果不一致,可能由基础生物学和研究结果的脆弱性解释。

主要发现

  • 抗GM-CSF治疗COVID-19的试验显示 divergent 结果。

临床怎么用

  • 需进一步研究COVID-19病理生理以更好靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Trials of anti-GM-CSF therapies in COVID-19 show divergent results; this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies. http://bit.ly/3O1AuIo Coronavirus disease 2019 (COVID-19) arises as a result of a pathological inflammatory response following infection with the coronavirus SARS-CoV-2. Although the majority of people infected with this virus will experience minimal or mild symptoms, a proportion will go on to develop more severe disease requiring hospitalisation and oxygen therapy. The most severe forms produce acute respiratory failure, necessitating mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The advent of SARS-CoV-2 vaccination has substantially altered the risk profile of COVID-19, with marked reductions in the severity of illness and hospitalisation. However, for unvaccinated patients and those who do not mount an effective immune response to vaccination, it remains a potentially lethal infection.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kohler K, Conway Morris A. GM-CSF targeting in COVID-19: an approach based on fragile foundations. Eur Respir J. 2023. PMID: 36396141. doi:10.1183/13993003.02091-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。